137 related articles for article (PubMed ID: 22074142)
1. Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.
Hasui T; Matsunaga N; Ora T; Ohyabu N; Nishigaki N; Imura Y; Igata Y; Matsui H; Motoyaji T; Tanaka T; Habuka N; Sogabe S; Ono M; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
J Med Chem; 2011 Dec; 54(24):8616-31. PubMed ID: 22074142
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
Hasui T; Ohyabu N; Ohra T; Fuji K; Sugimoto T; Fujimoto J; Asano K; Oosawa M; Shiotani S; Nishigaki N; Kusumoto K; Matsui H; Mizukami A; Habuka N; Sogabe S; Endo S; Ono M; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
Bioorg Med Chem; 2014 Oct; 22(19):5428-45. PubMed ID: 25187277
[TBL] [Abstract][Full Text] [Related]
3. (S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor.
Bell MG; Gernert DL; Grese TA; Belvo MD; Borromeo PS; Kelley SA; Kennedy JH; Kolis SP; Lander PA; Richey R; Sharp VS; Stephenson GA; Williams JD; Yu H; Zimmerman KM; Steinberg MI; Jadhav PK
J Med Chem; 2007 Dec; 50(26):6443-5. PubMed ID: 18038968
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.
Arhancet GB; Woodard SS; Iyanar K; Case BL; Woerndle R; Dietz JD; Garland DJ; Collins JT; Payne MA; Blinn JR; Pomposiello SI; Hu X; Heron MI; Huang HC; Lee LF
J Med Chem; 2010 Aug; 53(16):5970-8. PubMed ID: 20672820
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and structure-activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagonists.
Hasui T; Ohra T; Ohyabu N; Asano K; Matsui H; Mizukami A; Habuka N; Sogabe S; Endo S; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
Bioorg Med Chem; 2013 Oct; 21(19):5983-94. PubMed ID: 23958516
[TBL] [Abstract][Full Text] [Related]
6. Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors.
Fang X; Yin Y; Chen YT; Yao L; Wang B; Cameron MD; Lin L; Khan S; Ruiz C; Schröter T; Grant W; Weiser A; Pocas J; Pachori A; Schürer S; Lograsso P; Feng Y
J Med Chem; 2010 Aug; 53(15):5727-37. PubMed ID: 20684608
[TBL] [Abstract][Full Text] [Related]
7. Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.
Casimiro-Garcia A; Piotrowski DW; Ambler C; Arhancet GB; Banker ME; Banks T; Boustany-Kari CM; Cai C; Chen X; Eudy R; Hepworth D; Hulford CA; Jennings SM; Loria PM; Meyers MJ; Petersen DN; Raheja NK; Sammons M; She L; Song K; Vrieze D; Wei L
J Med Chem; 2014 May; 57(10):4273-88. PubMed ID: 24738581
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles.
Almansa C; Gómez LA; Cavalcanti FL; de Arriba AF; García-Rafanell J; Forn J
J Med Chem; 1997 Feb; 40(4):547-58. PubMed ID: 9046346
[TBL] [Abstract][Full Text] [Related]
9. Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.
Zehnder L; Bennett M; Meng J; Huang B; Ninkovic S; Wang F; Braganza J; Tatlock J; Jewell T; Zhou JZ; Burke B; Wang J; Maegley K; Mehta PP; Yin MJ; Gajiwala KS; Hickey MJ; Yamazaki S; Smith E; Kang P; Sistla A; Dovalsantos E; Gehring MR; Kania R; Wythes M; Kung PP
J Med Chem; 2011 May; 54(9):3368-85. PubMed ID: 21438541
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
[TBL] [Abstract][Full Text] [Related]
11. 1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists.
Tabrizi MA; Baraldi PG; Preti D; Romagnoli R; Saponaro G; Baraldi S; Moorman AR; Zaid AN; Varani K; Borea PA
Bioorg Med Chem; 2008 Mar; 16(5):2419-30. PubMed ID: 18077171
[TBL] [Abstract][Full Text] [Related]
12. Novel potent and selective thrombin inhibitors based on a central 1,4-benzoxazin-3(4H)-one scaffold.
Ilas J; Tomasić T; Kikelj D
J Med Chem; 2008 May; 51(9):2863-7. PubMed ID: 18412326
[TBL] [Abstract][Full Text] [Related]
13. Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists.
Elzein E; Kalla R; Li X; Perry T; Parkhill E; Palle V; Varkhedkar V; Gimbel A; Zeng D; Lustig D; Leung K; Zablocki J
Bioorg Med Chem Lett; 2006 Jan; 16(2):302-6. PubMed ID: 16275090
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
Verhoest PR; Chapin DS; Corman M; Fonseca K; Harms JF; Hou X; Marr ES; Menniti FS; Nelson F; O'Connor R; Pandit J; Proulx-Lafrance C; Schmidt AW; Schmidt CJ; Suiciak JA; Liras S
J Med Chem; 2009 Aug; 52(16):5188-96. PubMed ID: 19630403
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and pharmacological screening of novel antihypertensive agents using hybrid approach.
Bhandari SV; Bothara KG; Patil AA; Chitre TS; Sarkate AP; Gore ST; Dangre SC; Khachane CV
Bioorg Med Chem; 2009 Jan; 17(1):390-400. PubMed ID: 19036593
[TBL] [Abstract][Full Text] [Related]
16. Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.
Bolli MH; Marfurt J; Grisostomi C; Boss C; Binkert C; Hess P; Treiber A; Thorin E; Morrison K; Buchmann S; Bur D; Ramuz H; Clozel M; Fischli W; Weller T
J Med Chem; 2004 May; 47(11):2776-95. PubMed ID: 15139756
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
[TBL] [Abstract][Full Text] [Related]
18. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
Goldstein DM; Alfredson T; Bertrand J; Browner MF; Clifford K; Dalrymple SA; Dunn J; Freire-Moar J; Harris S; Labadie SS; La Fargue J; Lapierre JM; Larrabee S; Li F; Papp E; McWeeney D; Ramesha C; Roberts R; Rotstein D; San Pablo B; Sjogren EB; So OY; Talamas FX; Tao W; Trejo A; Villasenor A; Welch M; Welch T; Weller P; Whiteley PE; Young K; Zipfel S
J Med Chem; 2006 Mar; 49(5):1562-75. PubMed ID: 16509574
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
Quan ML; Lam PY; Han Q; Pinto DJ; He MY; Li R; Ellis CD; Clark CG; Teleha CA; Sun JH; Alexander RS; Bai S; Luettgen JM; Knabb RM; Wong PC; Wexler RR
J Med Chem; 2005 Mar; 48(6):1729-44. PubMed ID: 15771420
[TBL] [Abstract][Full Text] [Related]
20. Fluconazole analogues containing 2H-1,4-benzothiazin-3(4H)-one or 2H-1,4-benzoxazin-3(4H)-one moieties, a novel class of anti-Candida agents.
Borate HB; Maujan SR; Sawargave SP; Chandavarkar MA; Vaiude SR; Joshi VA; Wakharkar RD; Iyer R; Kelkar RG; Chavan SP; Kunte SS
Bioorg Med Chem Lett; 2010 Jan; 20(2):722-5. PubMed ID: 19963383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
